tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

SYRE Stock Latest News

Spyre Therapeutics initiated with early-stage designation at Goldman Sachs
The FlySpyre Therapeutics initiated with early-stage designation at Goldman Sachs
5d ago
SYRE
Oruka Therapeutics initiated with an Outperform at Wolfe Research
PremiumThe Fly
Oruka Therapeutics initiated with an Outperform at Wolfe Research
19d ago
APGE
ORKA
Spyre Therapeutics to be added to Nasdaq Biotechnology Index at open on 12/23
PremiumThe Fly
Spyre Therapeutics to be added to Nasdaq Biotechnology Index at open on 12/23
2M ago
SYRE
TD says Spyre has ‘superior TL1A program’ after Teva data
PremiumThe Fly
TD says Spyre has ‘superior TL1A program’ after Teva data
2M ago
SNY
SYRE
Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
PremiumThe Fly
Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG
2M ago
SYRE
TEVA
Spyre Therapeutics initiated with a Hold at JonesResearch
PremiumThe FlySpyre Therapeutics initiated with a Hold at JonesResearch
2M ago
SYRE
Spyre Therapeutics announces first participants dosed in Phase 1 trial
Premium
The Fly
Spyre Therapeutics announces first participants dosed in Phase 1 trial
3M ago
SYRE
Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50
Premium
The Fly
Spyre Therapeutics 7.275M share Spot Secondary priced at $27.50
3M ago
SYRE
Spyre Therapeutics Faces Internal Control Challenges
PremiumCompany Announcements
Spyre Therapeutics Faces Internal Control Challenges
3M ago
8K
SYRE
Spyre Therapeutics announces $200M common stock offering
PremiumThe Fly
Spyre Therapeutics announces $200M common stock offering
3M ago
SYRE
Spyre Therapeutics price target raised to $65 from $50 at Baird
PremiumThe Fly
Spyre Therapeutics price target raised to $65 from $50 at Baird
3M ago
SYRE
Spyre Therapeutics Reports Promising Trial Results for SPY001
PremiumCompany Announcements
Spyre Therapeutics Reports Promising Trial Results for SPY001
3M ago
8K
SYRE
Spyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
PremiumThe FlySpyre Therapeutics’ SPY001 shows efficacy, safety in Phase 1 bowel disease trial
3M ago
SYRE
Spyre Therapeutics Advances IBD Treatment Pipeline
Premium
Company Announcements
Spyre Therapeutics Advances IBD Treatment Pipeline
4M ago
SYRE
Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
Premium
The Fly
Spyre Therapeutics reports Q3 EPS ($1.36), consensus (82c)
4M ago
SYRE
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
PremiumThe Fly
Spyre Therapeutics price target raised to $65 from $50 at Guggenheim
4M ago
TAK
SYRE
Spyre Therapeutics Advances SPY003 for IBD Treatment
PremiumCompany Announcements
Spyre Therapeutics Advances SPY003 for IBD Treatment
4M ago
8K
SYRE
Spyre Therapeutics expects acceleration of SPY003 clinical timeline
PremiumThe Fly
Spyre Therapeutics expects acceleration of SPY003 clinical timeline
4M ago
SYRE
Spyre Therapeutics appoints Sloan as Chief Medical Officer
PremiumThe Fly
Spyre Therapeutics appoints Sloan as Chief Medical Officer
5M ago
SYRE
Spyre Therapeutics files to sell 46.33M shares of common stock for holders
PremiumThe FlySpyre Therapeutics files to sell 46.33M shares of common stock for holders
5M ago
SYRE
Spyre Therapeutics files $500M mixed securities shelf
Premium
The Fly
Spyre Therapeutics files $500M mixed securities shelf
6M ago
SYRE
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
6M ago
APGE
SYRE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >